Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Joseph G. Jemsek"'
Autor:
Joseph G. Jemsek, Frank Harrison
Publikováno v:
Infectious Diseases in Obstetrics and Gynecology, Vol 5, Iss 5, Pp 319-325 (1997)
Objective: The safety and efficacy of ampicillin plus sulbactam were compared with those of cefoxitin in the treatment of women with pelvic inflammatory disease (PID).
Externí odkaz:
https://doaj.org/article/abf9f18618fe48099dfb353348b41f33
Autor:
Kathryn L. Holloway, Joseph G. Jemsek, Ken W. Smith, Gregory Giguere, Jeffrey J. Collins, James E. Wilberger
Publikováno v:
Clinical Therapeutics. 18:84-94
Cefuroxime is a second-generation cephalosporin with in vitro activity against the organisms that are commonly associated with neurosurgical wound infections. Other properties of cefuroxime are an elimination half-life of 1.3 hours, which yields prol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d589b8245402c55c6143e05ff3cc16f
https://doi.org/10.1016/s0149-2918(96)80181-0
https://doi.org/10.1016/s0149-2918(96)80181-0
Autor:
Dianna Koontz, Douglas Barnas, Christian J. Bixby, Holly Bazmi, John W. Mellors, Joseph G. Jemsek
Background The rapid failure of initial therapy with combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that exclude zidovudine has not been fully explained by standard virus population analyses of HIV type-1 (HIV-1) drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6db4ead254b1301a7dc19c37f4ceecef
https://europepmc.org/articles/PMC2902251/
https://europepmc.org/articles/PMC2902251/
Autor:
Vadim Pokrovskiy, Carlos M. Pérez, Mustafa A. Noor, Nestor Sosa, Eduardo Arathoon, Michael Giordano, Michael Soccodato, Alexandra Thiry, Joseph G. Jemsek, Massimo Arlotti
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 42(2)
Protease inhibitor treatment of human immunodeficiency virus (HIV)-infected individuals has been linked to the development of lipodystrophy. The effects of atazanavir on body fat distribution and related metabolic parameters were examined in antiretr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0386fb6f1c6375685ef8ac0bef01550
https://pubmed.ncbi.nlm.nih.gov/16355342
https://pubmed.ncbi.nlm.nih.gov/16355342
Autor:
Shannon Schrader, Asda Vibhagool, Adriano Lazzarin, Willy Rozenbaum, Jean François Delfraissy, Antonio Rivero, Kathleen Squires, William G. Powderly, Jose M. Gatell, Michael Sension, Michael Giordano, Alexandra Thiry, Joseph G. Jemsek, Vadim Pokrovskiy
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 36(5)
Background: Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant Pl-associated dyslipidemia. Methods: A randomized, double-blind, double-dummy, active-controll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77732d4ff771c3196350560b3a432635
https://pubmed.ncbi.nlm.nih.gov/15247553
https://pubmed.ncbi.nlm.nih.gov/15247553
Autor:
David M. Parenti, Susan Swindells, Nancy Schoellkopf, Robert L. Murphy, John C. Pottage, Joseph G. Jemsek, Dolores M. Peterson, Robert Grosso, Joseph J. Eron, Gladys E. Sepulveda, Nicholaos C. Bellos, Michael Stevens, Jim Esinhart, Bruce Rashbaum
Publikováno v:
AIDS (London, England). 14(11)
Comparison of stavudine (d4T), didanosine (ddI) and indinavir (IDV) with zidovudine (ZDV), lamivudine (3TC) and IDV in HIV-1 infected patients.Randomized, open-label.Fourteen HIV Clinical Research Centers.Two-hundred and five patients with less than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da3f5704ba74c7cc85407798711530de
https://pubmed.ncbi.nlm.nih.gov/10983647
https://pubmed.ncbi.nlm.nih.gov/10983647
Autor:
Joseph Gathe, Edward Stool, Andrew T. Pavia, Joseph G. Jemsek, Anne Cross, John W. Mellors, Robert L. Murphy, Pierre Dellamonica, Lisa M. Dunkle, Spotswood L. Spruance
Publikováno v:
Annals of Internal Medicine. 126:355
Background: Stavudine is a promising antiretroviral agent, but its clinical efficacy has not been determined. Objective: To evaluate the clinical effect of stavudine (2',3'-didehydro-3'-deoxythymidine) monotherapy in patients with human immunodeficie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ce3e3cb6f1646b4c2a9778d1c2e0fa5
https://doi.org/10.7326/0003-4819-126-5-199703010-00003
https://doi.org/10.7326/0003-4819-126-5-199703010-00003
Autor:
William J. Robbins, Spotswood L. Spruance, Stephen J. Gabin, John J. Rinehart, Jean A. Smith, Ralph Zalusky, Allan R. Sampson, Jerome E. Groopman, Kay M. Larholt, Milan Fiala, Constance A. Benson, David H. Henry, John F. Toney, John C. Ruckdeschel, Thomas M. Hooton, Steven A. Miles, Michael S. Gottlieb, Lawrence A. Cone, Joseph G. Jemsek, Gildon N. Beall, Margaret A. Fischl, Randy L. Levine, Adan Rios, Robert I. Abels, Lawrence J. Eron, John T. Carey, Edward C. Bryant, Jeffrey E. Galpin, Seth A. Rudnick, Barbara Starrett
Publikováno v:
Annals of Internal Medicine. 117:739
OBJECTIVE To assess the effect of recombinant human erythropoietin (r-HuEPO) on anemia in patients with the acquired immunodeficiency syndrome (AIDS) who are receiving zidovudine therapy. DESIGN Combined analysis of four 12-week, randomized, double-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c56c24442845c06de5d93fa918d2bf3
https://doi.org/10.7326/0003-4819-117-9-739
https://doi.org/10.7326/0003-4819-117-9-739
Autor:
Seth A. Rudnick, Robert I. Abels, Richard A. Nelson, Alan S. Levin, Joseph G. Jemsek, David H. Henry, James D. Levine, Dorothy Thompson, Randy L. Levine
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 5:847
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9272cea9c8a3dd420a083ffb74ecd2cc
https://doi.org/10.1097/00126334-199208000-00013
https://doi.org/10.1097/00126334-199208000-00013
Antimicrobial Susceptibility Testing of Haemophilus parainfluenzae by a Kinetic Killing-Curve Method
Publikováno v:
Journal of Infectious Diseases. 141:310-316
A kinetic killing-curve method, designed to mimic several aspects of clinical therapy in endocarditis, was used to test 10 strains of Haemophilus parainfluenzae against 28 antibiotic regimens. In an effort to simulate changing in vivo levels of antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27b3709576100478342815f56ca2e310
https://doi.org/10.1093/infdis/141.3.310
https://doi.org/10.1093/infdis/141.3.310